Arca
Skip to content
Tools
Tools

VEGFB: Vascular endothelial growth factor B

Growth factor for endothelial cells.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on VEGFB, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1

Approved0

    Phase 31

    • Conbercept

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        ConberceptPhase 3Chengdu Kanghong Biotech Co., Ltd.Protein or peptideInhibitorVascular endothelial growth factor B inhibitor6

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
        LEAP Strategy for Neovascular Age-Related Macular DegenerationConberceptNot applicableNot yet recruitingChinese PLA General HospitalAug 4, 2026
        A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut MicrobiotaConberceptNot applicableNot yet recruitingFirst Affiliated Hospital of Zhejiang UniversityJul 22, 2026
        Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion TreatmentConberceptPhase 4RecruitingFirst Affiliated Hospital of Chongqing Medical UniversityAug 21, 2025
        Aqueous Humor Proteome in Retinal Vein Occlusion With Macular EdemaConbercept—Active, not recruitingTianjin Medical University Eye HospitalAug 6, 2025
        Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyConberceptNot applicableRecruitingWang YushengDec 5, 2024
        Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic RetinopathyConberceptPhase 4Active, not recruitingShanghai Eye Disease Prevention and Treatment CenterMar 12, 2024

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Macular retinal edema0.33
        • Age-related macular degeneration0.24
        • Neoplasm0.12
        • Type 2 diabetes mellitus0.11
        • Non-alcoholic fatty liver0.11

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3580488, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P49765, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.